The next frontier in myelofibrosis management
Activity Description / Statement of Need:
In this online, self-learning activity:
Myelofibrosis (MF) is a hematologic malignancy characterized by fibrosis buildup in the bone marrow, inadequate hematopoiesis, and splenomegaly. MF is a rare form of cancer, with an incidence of about 0.4 per 100,000 person-years in the United States. MF is the most aggressive form of the Philadelphia-negative, BCR-ABL1 chronic myeloproliferative neoplasms, with a five-year mortality rate of 51%. In patients with other comorbidities at the time of or after diagnosis, such as diabetes, hypertension, pulmonary diseases, or obesity, even greater reductions in lifespan can be expected. It has a considerable effect on patient quality of life and is associated not only with feelings of fear, anger, and grief common of an oncologic diagnosis, but also a gradual loss of ability to perform activities of daily living and hobbies. MF imposes a significant financial burden through direct and indirect costs, and patients who are diagnosed at a younger age often become unemployed as the disease progresses.
Target Audience:
The following HCPs: hematologists and oncologists in the community and academic settings; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and any other HCPs with an interest in or who clinically encounter patients with MF.
Cost: Free
View Offer chevron_rightDetails
Activity Description / Statement of Need:
In this online, self-learning activity:
Myelofibrosis (MF) is a hematologic malignancy characterized by fibrosis buildup in the bone marrow, inadequate hematopoiesis, and splenomegaly. MF is a rare form of cancer, with an incidence of about 0.4 per 100,000 person-years in the United States. MF is the most aggressive form of the Philadelphia-negative, BCR-ABL1 chronic myeloproliferative neoplasms, with a five-year mortality rate of 51%. In patients with other comorbidities at the time of or after diagnosis, such as diabetes, hypertension, pulmonary diseases, or obesity, even greater reductions in lifespan can be expected. It has a considerable effect on patient quality of life and is associated not only with feelings of fear, anger, and grief common of an oncologic diagnosis, but also a gradual loss of ability to perform activities of daily living and hobbies. MF imposes a significant financial burden through direct and indirect costs, and patients who are diagnosed at a younger age often become unemployed as the disease progresses.
Target Audience:
The following HCPs: hematologists and oncologists in the community and academic settings; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and any other HCPs with an interest in or who clinically encounter patients with MF.